Please wait a minute...

中国生物工程杂志

China Biotechnology
China Biotechnology  2011, Vol. 31 Issue (8): 124-132    DOI:
    
The Progress of Induced Pluripotent Stem Cells(iPS Cells)
MA Hai-bin1, HOU Ling-ling1, WANG Xiao-yu1, GUAN Wei-jun2, MA Yue-hui2
1. College of Life Sciences and Bioengineering of Beijing Jiaotong University,Beijing 100044, China;
2. Institute of Animal Sciences,Chinese Academy of Agricultural Sciences,Beijing 100193, China
Download: HTML   PDF(1747KB) HTML
Export: BibTeX | EndNote (RIS)      

Abstract  

Differentiated somatic cells can be reprogramed to induced pluripotent stem cells(iPS cells)by thansfection of a combination of specific genes,which is the most notable stem cell manufacturing technology in the stem cell research field in recent years.iPS cell not only is new model for the study of reprogramming mechanism of somatic cell,but also bring a new hope for the research of disease development mechanism and specific cell therapy. The preparation methods of iPS cells and related factors that influence transformation rate of iPS cells and pluripotency maintenance were summarized.



Key wordsiPS cells      Transformation rate      Pluripotency maintenance     
Received: 03 March 2011      Published: 25 August 2011
ZTFLH:  Q819  
Cite this article:

MA Hai-bin, HOU Ling-ling, WANG Xiao-yu, GUAN Wei-jun, MA Yue-hui. The Progress of Induced Pluripotent Stem Cells(iPS Cells). China Biotechnology, 2011, 31(8): 124-132.

URL:

https://manu60.magtech.com.cn/biotech/     OR     https://manu60.magtech.com.cn/biotech/Y2011/V31/I8/124


[1] Takahashi K,Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast culture by defined factors. Cell, 2006, 126:663-676.

[2] Yonehiro Kanemura. Development of cell-processing systems for human stem cells(neural stem cells,mesenchymal stem cells,and iPS cells)for regenerative medicine. Keio J Med, 2010, 59(2):35-45.

[3] Takahashi K,Tanabe K,Ohnuki M,et al.Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell, 2007, 13l(5):861-872.

[4] Yu J,Vodyanik M A,Smuga-Otto K,et al. Induced pluripotent stem cell lines derived from human somatic cells. Science, 2007, 318:1917-1920.

[5] Stadtfeld M,Hochedlinger K. Induced pluripotency:history,mechanisms,and applications. Genes Dev, 2010, 24(20):2239-2263.

[6] Zhao X Y,Li W,Lv Z,et al. iPS cells produce viable mice through tetraploid complementation. Nature, 2009, 461(7260):86-90.

[7] Nakagawa M,Takizawa N,Narita M,et al. Promotion of direct reprogramming by transformation-deficient Myc. Proc Natl Acad Sci USA, 2010,107(32):14152-14157.

[8] De Coppi P,Bartsch G Jr,Siddiqui M M,et al. Isolation of amniotic stem cell lines with potential for therapy. Nat Biotechnol, 2007, 25:100-106.

[9] Li C,Zhou J,Shi G,et al. Pluripotency can be rapidly and efficiently induced in human amniotic fluid-derived cells. Hum Mol Genet, 2009, 18(22):4340-4349.

[10] Raya A,Rodríguez-Pizà I,Guenechea G,et al. Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells. Nature, 2009, 460(7251):53-59.

[11] Stadtfeld M,Nagaya M,Utikal J,et al. Induced pluripotent stem cells generated without viral integration. Science, 2008, 322(5903):945-949.

[12] Honda A,Hirose M,Hatori M,et al. Generation of induced pluripotent stem cells in rabbits:potential experimental models for human regenerative medicine. J Biol Chem, 2010, 285(41):31362-31369.

[13] Yamanaka S. Patient-specific pluripotent stem cells become even more accessible. Cell Stem Cell, 2010, 7(1):1-2.

[14] Okita K,Nakagawa M,Hyenjong H,et al. Generation of mouse induced pluripotent stem cells without viral vectors. Science, 2008, 322(5903):949-953.

[15] Yu J,Hu K,Smuga-Otto K,et al. Human induced pluripotent stem cells free of vector and transgene sequences. Science, 2009, 324(5928):797-801.

[16] Okita K,Hong H,Takahashi K,et al. Generation of mouse-induced pluripotent stem cells with plasmid vectors. Nat Protoc, 2010, 5(3):418-428.

[17] Jia F,Wilson K D,Sun N,et al. A nonviral minicircle vector for deriving human iPS cells. Nat Methods, 2010,7(3):197-199.

[18] Woltjen K,Michael I P,Mohseni P,et al. piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells. Nature, 2009, 458(7239):766-770.

[19] Wang W,Lin C,Lu D,et al. Chromosomal transposition of PiggyBac in mouse embryonic stem cells. Proc Natl Acad Sci USA, 2008, 105(27):9290-9295.

[20] Ichida J K,Blanchard J,Lam K,et al. A small-molecule inhibitor of tgf-Beta signaling replaces sox2 in reprogramming by inducing nanog. Cell Stem Cell, 2009, 5(5):491-503.

[21] Zhu S,Li W,Zhou H,et al. Reprogramming of human primary somatic cells by OCT4 and chemical compounds. Cell Stem Cell, 2010, 7(6):651-655.

[22] Hong H,Takahashi K,Ichisaka T,et al. Suppression of induced pluripotent stem cell generation by the p53-p21 pathway. Nature, 2009, 460(7259):1132-1135.

[23] Utikal J,Polo J M,Stadtfeld M,et al. Immortalization eliminates a roadblock during cellular reprogramming into iPS cells. Nature, 2009, 460(7259):1145-1148.

[24] Marión R M,Strati K,Li H,et al. A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity. Nature, 2009, 460(7259):1149-1153.

[25] Li H,Collado M,Villasante A,et al. The Ink4/Arf locus is a barrier for iPS cell reprogramming. Nature, 2009, 460(7259):1136-1139.

[26] Zhao Y,Yin X,Qin H,et al. Two supporting factors greatly improve the efficiency of human iPSC generation. Cell Stem Cell, 2008, 3(5):475-479.

[27] Shi M,Liu D,Shen B,et al. Helpers of the cellular gatekeeper-miRNAs dance in P53 network. Biochim Biophys Acta, 2010, 1805(2):218-225.

[28] Huangfu D,Maehr R,Guo W,et al. Induction of pluripotent stem cells by defined factors is greatly improved by small-molecule compounds. Nat Biotechnol, 2008, 26(7):795-797.

[29] Yoshida Y,Takahashi K,Okita K,et al. Hypoxia enhances the generation of induced pluripotent stem cells. Cell Stem Cell, 2009, 5(3):237-241.

[30] Chen T,Yuan D,Wei B,et al. E-cadherin-mediated cell-cell contact is critical for induced pluripotent stem cell generation. Stem Cells, 2010, 28(8):1315-1325.

[31] Zhou Q,Yan B,Hu X,et al. Luteolin inhibits invasion of prostate cancer PC3 cells through E-cadherin. Mol Cancer Ther, 2009,8:1684-1691.

[32] Buszczak M,Paterno S,Spradling A C. Drosophila stem cells share a common requirement for the histone H2B ubiquitin protease scrawny. Science, 2009, 323(5911):248-251.

[33] Nishino J,Kim I,Chada K,et al. Hmga2 promotes neural stem cell self-renewal in young but not old mice by reducing p16Ink4a and p19Arf Expression. Cell, 2008, 135(2):227-239.

[34] Yang Y,Xu S,Xia L,et al. The bantam microRNA is associated with drosophila fragile X mental retardation protein and regulates the fate of germline stem cells. PLoS Genet, 2009, 5(4):1-10.

[35] Karumbayaram S,Novitch B G,Patterson M,et al. Directed differentiation of human-induced pluripotent stem cells generates active motor neurons. Stem Cells, 2009, 27(4):806-811.

[36] Kou Z,Kang L,Yuan Y,et al. Mice cloned from induced pluripotent stem cells(iPSCs). Biol Reprod, 2010, 83(2):238-243.

[37] Ueda K,Takano H,Niitsuma Y,et al. Sonic hedgehog is a critical mediator of erythropoietin-induced cardiac protection in mice. J Clin Invest, 2010, 120(6):2016-2029.

[38] Bhutani N,Brady J J,Damian M,et al. Reprogramming towards pluripotency requires AID-dependent DNA demethylation. Nature, 2010, 463(7284):1042-1047.

[39] Nakagawa M,Takizawa N,Narita M,et al. Promotion of direct reprogramming by transformation-deficient Myc. Proc Natl Acad Sci U S A, 2010, 107(32):14152-14157.

[40] Sun N,Longaker M T,Wu J C. Human iPS cell-based therapy:considerations before clinical applications. Cell Cycle,2010,9(5):880-885.

[41] Li R,Liang J,Ni S,et al. A mesenchymal-to-epithelial transition initiates and is required for the nuclear reprogramming of mouse fibroblasts. Cell Stem Cell, 2010, 7(1):51-63.

[1] WU Sheng-xing, LI Yan, ZHANG Hai-yan, LIU Yang, LAI Qiong, YANG Ming. The Prospect of Induction of Pluripotent Stem Cell Technology in Drug Research and Development[J]. China Biotechnology, 2017, 37(11): 116-122.